Estrella Immunopharma (ESLA) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Passage Bio (PASG) has outperformed Estrella Immunopharma (ESLA) over the past year, losing 54.3% versus a loss of 67.9%. Over five years, ESLA leads with a -95.8% price change compared with -98.1% for PASG. Estrella Immunopharma is the larger company by market cap ($18.2 million vs $12.2 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | PASG |
|---|---|---|
| Share price | $0.4175 | $3.78 |
| Market cap | $18.16M | $12.16M |
| 1-day change | -0.43% | -1.95% |
| YTD return | -73.24% | -67.97% |
| 1-year return | -67.88% | -54.35% |
| 5-year return | -95.77% | -98.06% |
| EPS (TTM) | $-0.25 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $20.00 |
| 52-week low | $0.3611 | $3.29 |
| Distance from 52-week high | -86.75% | -81.10% |
| Average volume | 38.27K | 26.16K |
| Shares outstanding | 43.50M | 3.22M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed ESLA by 13.5 percentage points over the past year.
ESLA vs PASG FAQ
Which is bigger, Estrella Immunopharma or Passage Bio?
Estrella Immunopharma (ESLA) is larger, with a market capitalization of $18.16M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, ESLA or PASG?
PASG returned -54.35% over the past 12 months, compared with -67.88% for ESLA (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.